Apotex Health IPO Expected at Top of C$24 Range

By EC Assets · Published 9 June 2026

Apotex Health's initial public offering is anticipated to price at C$24 per share. This expected pricing is at the top of its indicated range. The Canadian drug maker filed for a Toronto IPO. Apotex Health is seeking to raise 1.2 billion Canadian dollars through its Toronto IPO. The firm aims for a valuation exceeding C$5 billion in its Canadian IPO. Apotex is testing the TSX with a C$1 billion listing. This IPO could revive the Canadian market for such listings. Apotex Health and Quantinuum signal market momentum with their listings. BNN Bloomberg reported on Apotex filing for its Toronto IPO. Apotex recently launched generic Semaglutide in Canada. This launch was through a partnership, marking its first international rollout of a generic GLP-1. This article is intended for informational purposes only. It does not constitute investment advice.